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Summary
HER2/Neu genemutations have been identified in lung cancer. Expression of aHER2mutant containing aG776YVMA insertion
in exon 20 was more potent than wild-type HER2 in associating with and activating signal transducers, phosphorylating
EGFR, and inducing survival, invasiveness, and tumorigenicity. HER2YVMA transphosphorylated kinase-dead EGFRK721R
and EGFRWT in the presence of EGFR tyrosine kinase inhibitors (TKIs). Knockdown of mutant HER2 in H1781 lung cancer
cells increased apoptosis and restored sensitivity to EGFR TKIs. The HER2 inhibitors lapatinib, trastuzumab, and CI-1033
inhibited growth of H1781 cells and cells expressing exogenous HER2YVMA. These data suggest that (1) HER2YVMA activates
cellular substrates more potently than HER2WT; and (2) cancer cells expressing this mutation remain sensitive to HER2-
targeted therapies but insensitive to EGFR TKIs.Introduction
HER2/Neu (ErbB2) is a member of the ErbB family of transmem-
brane receptor tyrosine kinases, which also includes the epider-
mal growth factor receptor (EGFR, ErbB1), HER3 (ErbB3), and
HER4 (ErbB4). Binding of ligands to the ectodomain of EGFR,
ErbB3, and ErbB4 results in the formation of catalytically active
homo- and heterodimers to which HER2 is recruited as a pre-
ferred partner (Yarden and Sliwkowski, 2001). Although HER2
cannot bind any of the ErbB ligands directly, its catalytic activity
can potently amplify signaling by ErbB-containing heterodimers
via increasing ligand binding affinity and/or receptor recycling
and stability (Graus-Porta et al., 1997; Pinkas-Kramarski et al.,
1996; Wang et al., 1998; Worthylake et al., 1999). Activation
of the ErbB network leads to receptor autophosphorylation
in C-terminal tyrosines and the recruitment to these sites ofCANCER CELL 10, 25–38, JULY 2006 ª2006 ELSEVIER INC. DOI 10.101cytoplasmic signal transducers that regulate cellular processes
such as proliferation, differentiation, motility, adhesion, protec-
tion from apoptosis, and transformation. Cytoplasmic signal
transducers that are activated by this network include PLC-g1,
Ras-Raf-MEK-MAPKs, phosphatidylinositol-3 kinase (PI3K)-
Akt-ribosomal S6 kinase, Src, the stress-activated protein ki-
nases (SAPKs), PAK-JNKK-JNK, and the signal transducers
and activators of transcription (STATs) (Yarden and Sliwkowski,
2001).
HER2 gene amplification has been reported in approximately
20% of metastatic breast cancers, where it is associated with
poor patient outcome (Slamon et al., 1989). Trastuzumab, a hu-
manized monoclonal IgG1 that binds the extracellular domain of
HER2, has been shown to induce clinical responses in HER2-
overexpressing breast cancers and prolong patient survival
(Slamon et al., 2001; Vogel et al., 2002). HER2 is overexpressedS I G N I F I C A N C E
Mutations in the kinase domain of the HER2/Neu proto-oncogene were identified recently. Expression of a HER2 mutant containing
aG776YVMA insertion in exon 20 wasmore potent thanwild-type HER2 in activating postreceptor signal transducers and in transforming
mammary and bronchial epithelial cells. HER2YVMA activated the EGFR in the presence of EGFR tyrosine kinase inhibitors (TKIs). Knock-
downofmutant HER2 in H1781 lung cancer cells inducedcell death and sensitized these cells to EGFR TKIs. The HER2 inhibitors lapatinib,
trastuzumab, andCI-1033 inhibited growth of cells expressingmutant HER2. These data suggest that (1) HER2YVMA signalsmore potently
than HER2WT; and (2) cancer cells harboring exon 20 insertions in HER2 remain sensitive to HER2-targeted therapies but insensitive to
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A R T I C L Ein a cohort of non-small cell lung cancers (NSCLCs), and in-
creased HER2 gene copy number has been associated with
therapeutic response to EGFR tyrosine kinase inhibitors (TKIs)
(Cappuzzo et al., 2005; Hirsch et al., 2002). Recently, intragenic
somatic mutations in the HER2 gene were reported in <5% of
NSCLCs. These involve in-frame duplications/insertions in a
small stretch within exon 20 that correspond to the identical
nine codon region in exon 20 of the EGFR gene, where duplica-
tions/insertions have also been reported (Stephens et al., 2004).
Interestingly, mutations in both receptor genes do not overlap
and occur predominantly in patients of Asian ethnicity, non-
smokers, females, and lung adenocarcinomas (Shigematsu
et al., 2005). Because of the location of these insertions at the
C-terminal end of the aC helix in the tyrosine kinase domain, it
has been postulated that they result in a conformational change
and shift in the helical axis, thus narrowing the ATP binding cleft
and increasing kinase activity over that in wild-type receptors
(Gazdar et al., 2004).
To study the potential gain-of-function effects of HER2muta-
tions, we generated a retroviral vector encoding HER2 with an
in-frame YVMA insertion at residue 776, which is the most com-
mon abnormality detected in a recent survey in 96 unselected
NSCLC specimens (Shigematsu et al., 2005). Stable expression
of HER2YVMA in BEAS2B bronchial and MCF10A mammary
epithelial cells resulted in enhanced transformation compared
to cells transduced with wild-type HER2. HER2YVMA was po-
tently autophosphorylated and induced transphosphorylation
of kinase-dead EGFR and HER3 as well as higher association
with signal transducers that activate proliferative and antiapop-
totic pathways compared to HER2WT. RNA interference of mu-
tant but not wild-type HER2 in a lung cancer cell line containing
a VC insertion at G776 in exon 20 inhibited antiapoptotic signals
and induced tumor cell death. Cells expressing HER2YVMA or
HER2VC exhibited resistance to the EGFR TKIs such as erlotinib
and gefitinib but remained sensitive to direct HER2 inhibitors
such as the receptor antibody trastuzumab and the small mole-
cule dual kinase inhibitors lapatinib and CI-1033.
Results
Transient and stable expression of HER2YVMA mutant
We generated a retroviral vector encoding Myc-tagged full-
lengthHER2YVMA (Figure S1A in theSupplemental Data available
with this article online). Vectors expressing wild-type HER2
(HER2WT) and HER2YVMA were transiently transfected into 293
human embryonic kidney cells. Cells expressingHER2YVMA con-
tained higher levels of phosphorylatedMAPK and Akt compared
to vector- or HER2WT-transfected cells (Figure S1B, lanes 1–3).
In immunoblots of Myc pull-downs, HER2YVMA showed higher
tyrosine phosphorylation and stronger associations with the
adaptor proteinsShcandp85compared toHER2WT (FigureS1B,
lanes 4–6).
Human immortalized BEAS2B bronchial and MCF10A mam-
mary epithelial cells were then stably transducedwith HER2YVMA
orHER2WT retroviral vectors. After single colony selection, trans-
gene expressionwasdetected byMycandHER2 immunoblot. In
both lines, HER2YVMA-transfected clones exhibited higher levels
of a tyrosine phosphorylated protein that comigrated with the
HER2 and Myc bands compared to clones expressing HER2WT
(Figures S1C and S1D). BEAS2B and MCF10A clones26expressing equal levels ofHER2WTandHER2YVMAwere selected
for subsequent functional studies.
HER2YVMA is more transforming than HER2WT
in bronchial epithelial cells
We next determined the transforming effects of HER2YVMA on
bronchial epithelial cells. BEAS2B cells expressing HER2YVMA
proliferated faster than cells expressingHER2WTor empty vector
in both serum-containing and serum-free medium (Figure 1A).
Cell survivalwas assessedbyApo-BrdUassay. After serumstar-
vation for 3 days, 16%–18% of the BEAS2B cells expressing
HER2WT or vector exhibited evidence of apoptosis as measured
by the incorporation of Br-dUTP into double-stranded DNA.
However, expression of HER2YVMA protected the cells from ap-
optosis induced by serum starvation (Figure 1B). Similar results
were obtained in anchorage-independent colony-forming
assays. Ten days after seeding in soft agar, cells expressing
HER2YVMA formed 40% more and significantly larger colonies
than HER2WT-expressing cells (Figure 1C). To determine if in-
creased focus formation correlated with tumorigenicity in vivo,
cells were injected in athymic nude mice. Ten days after s.c. in-
oculation, four out of six mice injected with cells expressing
HER2YVMA exhibited established tumors, whereas no tumor
was detected in animals injected with cells expressing HER2WT
or vector alone (Figure 1D). Finally, we examined the effect of
theHER2 insertionmutation on cell motility. HER2YVMA-express-
ing cells migrated into the wounded area and closed the wound
within 24 hr, whereas in BEAS2B/HER2WT cells the wound re-
mained open. Similar results were obtained in transwell assays,
where cells expressing the insertion mutant exhibited 3-fold
increased migration through 5 mm pore size filters (Figure 1E).
HER2YVMA is a more potent suppressor of apoptosis
than HER2WT in mammary epithelial cells
The transforming effects of ectopic HER2WT have been well
characterized in MCF10A human mammary epithelial cells
(Debnath and Brugge, 2005). In these cells, endogenous HER2
protein levels are undetectable (Figure S1D). Compared to the
modest proliferative effect of transfected HER2WT over vector
controls, stable expression of HER2YVMA resulted in accelerated
anchorage-dependent growth (Figure 2A). MCF10A cells form
polarized, quiescent acini-like spheroids in three-dimensional
(3D) basement membrane gels. Activation of chimeric ErbB2
in these cells reinitiates proliferation, disrupts tight junctions
and apical polarity, and induces acinar expansion but without in-
vasion into the surrounding matrix. MCF10A cells expressing
HER2WT or HER2YVMA were grown on Matrigel containing base-
ment membrane components. As early as day 4, HER2YVMA-
expressing cells formed multiacinar structures that by day 14
exhibited invading protrusions into the surrounding matrix.
This process was more delayed with MCF10A/HER2WT cells,
which developed into smaller multiacinar structures with a hol-
low lumen (Figure 2B, days 14–16, arrows). Acini were trypsi-
nized and cell numbers were determined at regular intervals.
MCF10A/HER2YVMA cells continued to proliferate up to 16
days, whereas the slower proliferation of HER2WT cells reached
a plateau after day 10 (Figure 2C). The large multiacinar struc-
tures formed by HER2YVMA-expressing cells suggested a more
invasive phenotype. Therefore, we examined the ability of the
cells to invade through Matrigel-coated chambers. Cells were
seeded on top of a Matrigel invasion chamber and allowed toCANCER CELL JULY 2006
A R T I C L EFigure 1. HER2YVMA is potently transforming in bronchial epithelial cells
A: BEAS2B cells stably expressing HER2WT, HER2YVMA, or vector were seeded on 12-well plates and allowed to grow in full growth medium or serum-free medium.
Cells were trypsinized and counted every 24 hr. Each data point represents the mean 6 SD of four wells.
B: Stably transduced BEAS2B cells were maintained in growth medium or serum starved for 3 days before being subjected to Apo-BrdU assay as described in
Experimental Procedures. The percentage of FITC+ (apoptotic) cells is indicated. Quantitative data represent the mean 6 SD of three experiments.
C: Stably transduced BEAS2B cells were seeded in colony-forming assay as described in Experimental Procedures. Colonies were photographed at day 10.
D: The indicated BEAS2B cells (23 106) were injected s.c. in athymic nude mice. Detectable tumors ofR3 mm in minimal diameter are shown (n = 6 per group).
E: Left panel: close-to-confluent monolayers of BEAS2B cells in serum-free medium were wounded with a pipette tip; wound closure was monitored at the
indicated times. Right panel: transwell assays. Cells that had migrated to the underside of transwell filters are shown after fixation. Quantitative data are
depicted below, with each bar representing the mean 6 SD of six fields from three independent experiments.invade into it for 24 hr. Compared to controls, HER2WT and
HER2YVMA cells invaded 3-fold and 10-fold more the other
side of the Matrigel chamber, respectively (Figure 2D).
In cell survival assays, both MCF10A/HER2WT and vector
control cells exhibited 58%–62% apoptosis after 3 days of se-
rum starvation, whereas cells expressing the insertion mutant
were protected from apoptosis (Figure 2E). Cells in the center
of MCF10A polarized acini grown in 3D have been shown to un-
dergo apoptosis resulting in the formation of a central lumen.
Apoptosis and lumen formation have been shown to be pre-
vented by the expression of activated oncogenes (Debnath
et al., 2002). Thus, we subjected MCF10A acini to immunofluo-
rescence staining of cleaved (active) caspase-3, an apoptosis
marker, and Ki-67, a proliferationmarker. In day 8 HER2WT acini,
the centrally located cells underwent apoptosis, as indicated by
caspase-3 staining. However, caspase-3 was undetectable in
HER2YVMA acini (Figure 2F). In day 14 HER2WT acini, Ki-67 stain-
ing was mostly located at the edges, whereas in HER2YVMA-ex-
pressing acini, both peripheral and centrally located cells were
proliferating (Ki-67+; Figure 2G).CANCER CELL JULY 2006HER2YVMA kinase has stronger catalytic
activity than HER2WT
ErbB receptor chimeras containing the ligand binding domain
of FK506 binding protein (FKBP) can be induced to homodi-
merize by the bivalent ligand AP1510 and, therefore, provide
a method to elucidate the activity of ectopic ErbB homo-
and heterodimers without interference from the endogenous
ErbB receptors (Muthuswamy et al., 1999). Thus, we con-
structed HER2 chimeras containing the extracellular and
transmembrane domains of low-affinity NGF receptor (p75),
the kinase domain (aa 676–1255) of HER2YVMA or HER2WT,
and two copies of FKBP with an HA tag at the carboxyl termi-
nus. MCF10A cells stably expressing equal levels of the
two chimeras were treated with AP1510 to induce receptor
homodimerization. In cells expressing the wild-type chimera,
HER2WT phosphorylation was modestly induced by AP1510.
However, in cells expressing the mutant chimera, HER2YVMA
phosphorylation was high in the absence of AP1510 and
induced further by the addition of the dimerizing ligand
(Figure 3A).27
A R T I C L E28 CANCER CELL JULY 2006
A R T I C L EFigure 3. HER2YVMA has a more potent kinase activity compared to HER2WT
A: MCF10A cells stably expressing HER2WT or HER2YVMA chimeras or empty vector were serum starved for 24 hr before treatment with 1 mM AP1510 for 15 min.
Cell lysates were precipitated with an HA antibody; the HA pull-downs were subjected to P-Tyr and HA immunoblot analysis as indicated in Experimental
Procedures.
B: 32D cells stably expressing full-length HER2WT, HER2YVMA, or vector control were serum starved for 4 hr, lysed, and subjected to the indicated immunoblot
analyses.
C: HER2WT or HER2YVMA receptors expressed in MCF10A cells were precipitated with a Myc antibody. An in vitro kinase assay was performed as described in
Experimental Procedures, and the products were analyzed by 7.5% SDS-PAGE followed by P-Tyr and Myc immunoblots.In 32Dmurine hematopoietic cells that do not express endog-
enous ErbB receptors or ligands (Pierce et al., 1988), expression
of equal levels of the full-length receptors also showed a higher
constitutive phosphorylation of HER2YVMA compared to
HER2WT using an antibody that recognizes HER2 phosphory-
lated at Y1248 (DiGiovanna and Stern, 1995) (Figure 3B). In-
creased autophosphorylation of HER2YVMA could result from
either increased receptor homodimerization (Figure 3A) and/or
a more potent kinase activity. To further test this second possi-
bility, Myc-tagged wild-type and mutant HER2 were precipi-
tated from MCF10A/HER2WT and MCF10A/HER2YVMA cells, re-
spectively, and the pull-downs were tested in an in vitro kinase
reaction. When ATP was added, HER2YVMA showed markedly
higher tyrosine phosphorylation than HER2WT (Figure 3C), sug-
gesting that the insertion mutant has higher autocatalytic activ-
ity. Similar results were obtained with wild-type and mutant
HER2 precipitated from 32D cells (data not shown).
HER2YVMA associates with and activates the EGFR
in the absence of ErbB ligands and EGFR kinase activity
We next examined the ability of HER2YVMA to associate with and
activate exogenous substrates. To minimize ligand-induced re-
ceptor activity, cells were serum starved 24 hr prior to experi-
mental manipulation. In both BEAS2B and MCF10A cells stablyCANCER CELL JULY 2006transduced with HER2YVMA, HER2WT, or vector alone, the levels
of EGFR, Shc, p85, MAPK (ERK), and Akt were the same. How-
ever, basal levels of Y1068 P-EGFR, Y416 P-Src, P-Akt, and P-
MAPKweremarkedly higher in HER2YVMA compared to HER2WT
cells (Figure 4A, lanes 1–6). To determine the activation status of
ectopic HER2, Myc pull-downs were tested by P-Tyr and Y1248
P-HER2 immunoblots. Y1248 P-HER2 was only detected in the
Myc precipitate from HER2YVMA-expressing cells. A much
stronger P-Tyr band coprecipitated withMyc in these cells com-
pared with HER2WT-expressing cells. The fainter P-Tyr band in
HER2WT cells, where Y1248 P-HER2 was not detected in the
Myc precipitates, suggests that HER2 is phosphorylated in tyro-
sines other than Y1248 in MCF10A/HER2WT cells. Finally, higher
levels of EGFR, Y1068 P-EGFR, Shc, and p85 coprecipitated
with Myc in cells expressing the insertion mutant compared to
HER2WT cells (Figure 4A, lanes 7–12). Higher levels of Y1289
P-HER3 and increased HER3:HER2 association were observed
in HER2YVMA-expressingMCF10A cells but not in BEAS2B cells,
probably as a result of the lower levels of HER3 in the latter cells
(Figure 4A).
In BEAS2B/HER2WT cells, TGFa stimulated anchorage-
dependent growth (Figure S2A), EGFR (Y1068) and HER2
(Y1248) phosphorylation, and activation of Akt and MAPK
(Figure S2B, lanes 1–4). Conversely, the addition of TGFa didFigure 2. HER2YVMA induces a gain of function over HER2WT in mammary epithelial cells
A: MCF10A cells seeded on 12-well plates in full growth medium were trypsinized and counted every 24 hr. Each data point represents the mean6 SD of four
wells.
B: Phase contrast images of HER2WT- or HER2YVMA-expressing MCF10A acini cultured on basement membrane in 8-well chambers and followed every 2 days.
Scale bars, 50 mm.
C: MCF10A acini (from B) were trypsinized and counted every 48 hr. Each data point represents the mean 6 SD of four wells.
D: Stably transduced MCF10A cells were seeded at 2.53 104 cells/well on Matrigel-coated transwells and allowed to invade toward growth medium. At 24 hr
invading cells were counted; each bar represents the mean 6 SD of three wells.
E: MCF10A cells were maintained in growth medium or serum starved for 3 days before being subjected to Apo-BrdU assay as described in Experimental
Procedures. The mean percentage 6 SD of FITC+ apoptotic cells from three wells is indicated.
F: MCF10A cells expressing HER2WT or HER2YVMA were cultured on basement membrane for 8 days and stained with antibodies against b-catenin (green) and
cleaved caspase-3 (red).
G: Transduced MCF10A cells were cultured on basement membrane for 14 days and stained with Ki-67 (green) and Myc tag (red) antibodies. Scale bars,
50 mm. In both panels, serial confocal sections of the stained acini were photographed at 2.96 mm intervals.29
A R T I C L EFigure 4. HER2YVMA induces ligand-independent EGFR phosphorylation, which does not require the EGFR tyrosine kinase
A: BEAS2B and MCF10A cells expressing HER2WT, HER2YVMA, and vector were serum starved for 24 hr, lysed, and then subjected to SDS-PAGE or precipitation
with a Myc tag antibody. Total cell lysates (left) and Myc pull-downs were tested by immunoblots with the indicated antibodies.
B: MCF10A cells were serum starved for 24 hr and treated with 10 ng/ml EGF. At 0–30 min, the monolayers were lysed and the cell lysates subjected to the
indicated immunoblot analyses. For P-HER2, lysates were immunoprecipitated with HER2 antibody followed by immunoblot with P-Tyr monoclonal antibody.
Where indicated, 1 mM gefitinib was added 4 hr prior to EGF.
C:HER2WT or HER2YVMA receptors expressed in MCF10A cells were precipitated with a Myc antibody. EGFRK721R (EGFRKD)-GFP expressed in 32D cells was pulled
down with a GFP antibody. An in vitro kinase assay was performed as described in Experimental Procedures, and the products were analyzed by 7.5% SDS-
PAGE followed by P-Tyr, Myc, and EGFR immunoblot analyses. The molecular weights (in kDa) are shown at the left of the gel. Positions of EGFRKD-GFP and
HER2 receptors are indicated by arrows.not increase the high basal phosphorylation of EGFR, HER2,
Akt, andMAPK in cells expressing HER2YVMA (Figure S2B, lanes
5–8), nor did it stimulate monolayer growth (Figure S2A). Similar
results were observed in MCF10A cells. Treatment with EGF po-
tently induced Y1068 EGFR, HER2, MAPK, and Akt phosphory-
lation in MCF10A/HER2WT. However, in HER2YVMA-expressing
cells, EGF only modestly increased the high basal P-HER2
and EGFR phosphorylation at Y1068 and Y845 (Figure 4B).30Further, recombinant EGF stimulated proliferation andmigration
in MCF10A cells expressing HER2WT but had no effect in cells
expressing HER2YVMA (Figures S2C and S2D).
In cells expressing HER2WT, ligand-induced Y1068 P-EGFR,
P-HER2, P-MAPK, and P-Akt were efficiently blocked by the
EGFR small molecule TKI gefitinib. However, gefitinib had little
or no effect on EGFR, HER2, MAPK, and Akt phosphorylation
in MCF10A/HER2YVMA cells in the presence or absence ofCANCER CELL JULY 2006
A R T I C L Eadded ligand. In both cell types, gefitinib did not block EGFR
phosphorylation at Y845 (Figure 4B). Phosphorylation of this
residue does not depend on EGFR tyrosine kinase activity
(Stover et al., 1995) and has been shown to be induced by
c-Src (Biscardi et al., 1999), consistent with the higher levels of
P-Src in cells expressing HER2YVMA (Figure 4A). The results
with gefitinib suggested that the EGFR/HER2 association and
EGFR phosphorylation in cells expressing HER2YVMA did not re-
quire EGFR’s catalytic activity. Therefore, we performed an
in vitro kinase assay using GFP-fused K721R (kinase-dead)
EGFR (Ewald et al., 2003) (EGFRKD) as substrate. Myc-tagged
wild-type and mutant HER2 receptors were precipitated from
transfected MCF10A cells and incubated with EGFRKD-GFP in
thepresence or absenceof ATP. In the absence of ATP, nophos-
phorylation of EGFRKD-GFP was detected. Both HER2WT and
HER2YVMA phosphorylated EGFRKD-GFP in vitro, but this effect
was at least 5-fold higher with the insertion mutant (Figure 4C).
Cells expressing HER2YVMA are resistant to EGFR
inhibitors but still sensitive to HER2 inhibitors
The EGFR TKIs erlotinib and gefitinib inhibited the weak basal
EGFR phosphorylation in MCF10A/HER2WT cells (Figure 5A,
lanes 1–11). Although not direct inhibitors of HER2, it has been
shown that (EGFR-specific) low concentrations of erlotinib or
gefitinib inhibit HER2 phosphorylation and growth of HER2-de-
pendent tumor cells, presumably by blocking the EGFR tyrosine
kinase and, thus, interfering with EGFR-HER2 crosstalk and
heterodimerization (Hernan et al., 2003; Moasser et al., 2001;
Moulder et al., 2001). Consistent with this, erlotinib and gefitinib
suppressed HER2WT cell proliferation in a dose-dependent
manner (Figure S3, top) and inhibited the 3D growth of these ac-
ini inMatrigel devoid of added EGFR ligands (Figure 5C, top). On
the other hand, the ability of HER2YVMA to transactivate the
EGFR in an EGFR kinase-independent manner anticipated
lack of an inhibitory effect of EGFR TKIs against cells expressing
the insertion mutant. Indeed, erlotinib and gefitinib had no effect
on EGFR and HER2 phosphorylation in MCF10A/HER2YVMA
cells (Figure 5A, lanes 15–25) nor inhibited their growth in mono-
layer (Figure S3, bottom) or in 3D inMatrigel (Figure 5C, bottom).
We next examined the effect of direct inhibitors of HER2 on
the insertion mutant. Treatment with the HER2 antibody trastu-
zumab downregulated both wild-type and mutant receptors
from the cell surface, as indicated by HER2 immunoblot of
streptavidin precipitates of surface-biotinylated cells (Figure 5B).
However, treatment with trastuzumab inhibited growth and inva-
siveness of HER2YVMA but notHER2WT acini in 3D. This lack of an
effect of trastuzumab on cells overexpressingHER2WT is consis-
tent with the reported inability of the IgG1 to interfere with EGF,
TGFa, and heregulin-induced growth and/or EGFR/HER2 heter-
odimerization (Agus et al., 2002; Moulder et al., 2001; Ye et al.,
1999). The EGFR/HER2 dual TKI lapatinib (Rusnak et al., 2001)
inhibited EGFR and HER2 phosphorylation in MCF10A/HER2WT
cells (Figure 5A, lanes 12–14). Lapatinib also inhibitedHER2YVMA
and EGFR phosphorylation in HER2YVMA cells but at higher con-
centrations (Figure 5A, lanes 26–28). Trastuzumab alone or in
combination with lapatinib also suppressed Y1068 P-EGFR
(Figure S4). The growth in 3D of HER2YVMA-expressing acini
was also suppressed by lapatinib, although not as much as
with MCF10A/HER2WT acini (Figure 5C). The combination of
lapatinib and trastuzumab was the most potent in suppressing
growth of HER2YVMA acini (Figure 5C). Addition of erlotinib orCANCER CELL JULY 2006gefitinib did not enhance the effect of trastuzumab against these
cells (data not shown). At day 8 and day 14, HER2YVMA acini
treated with both drugs exhibited apoptotic cells in the center,
similar to those exhibited byHER2WT acini (Figure 5D, compared
to Figures 2F and 2G). These data suggest that HER2YVMA is still
sensitive to direct inhibitors of HER2.
Mutant HER2 in H1781 cells is required for proliferation
and survival
NCI-H1781 lung cancer cells express wild-type EGFR and con-
tain a VC insertion at G776 in exon 20 of the HER2 gene (Shige-
matsu et al., 2005) (Figure S1A). Small interfering RNA oligonu-
cleotides targeting HER2WT, HER2MUT, or a control sequence
were transfected into H1781 cells. Three days posttransfection,
we used a PCR primer set specific for mutant HER2 mRNA and
observed efficient knockdown of HER2MUT in cells expressing
siRNA targeting HER2MUT but not HER2WT. The HER2mutation
in H1781 cells has been reported to be homozygous (Shige-
matsu et al., 2005), explaining the lack of HER2WT mRNA ex-
pression by RT-PCR (Figure 6A). By immunoblot analysis,
RNAi resulted in 90% reduction of mutant HER2 protein as
well as basal P-MAPK and P-Akt (Figure 6B). These cells ex-
hibited markedly increased apoptosis (by cleaved caspase-3
staining) and decreased proliferation (by Ki-67 staining), com-
pared to cells transfected with siRNA targeting HER2WT or the
control sequence (Figure 6C). Similar to MCF10A/HER2YVMA
cells, trastuzumab, lapatinib, and the combination, but not erlo-
tinib and gefitinib, inhibited H1781 colony formation (Figure 6D).
In cells expressing siRNA targeting HER2MUT but not in control
cells, erlotinib and gefitinib reduced H1781 colony formation
(Figure 6D), suggesting that the insertion mutant counteracts
the inhibitory effect of the EGFR TKIs.
The irreversible ErbB2 inhibitor CI-1033 is a potent
inhibitor of the mutant HER2
It has been shown that a mutant EGFR with an exon 20 insertion
is resistant to gefitinib and erlotinib but highly sensitive to the ir-
reversible covalent EGFR/HER2 inhibitor CL-387,785 (Greulich
et al., 2005). Therefore, we tested the effect of a similar irrevers-
ible inhibitor, the 4-anilinoquinazoline CI-1033, which is pre-
dicted to covalently modify Cys773 within the ATP binding site
of the HER2 kinase (Citri et al., 2002; Smaill et al., 2000). In
dose-dependent fashion, submicromolar concentrations of
CI-1033 inhibited tyrosine phosphorylation of wild-type andmu-
tant HER2 and EGFR in transfected MCF10A and H1781 cells
(Figure 7A). The same range of concentrations (0.1–3 mM) mark-
edly inhibited growth on Matrigel of both MCF10A/HER2WT and
MCF10A/HER2YVMA cells, but the dose response was steeper
against cells expressing the mutant (Figure 7B). Similar concen-
trations of CI-1033 also inhibited H1781 colony formation in soft
agar with a 25% and 90% reduction in colony number at 0.1 and
1 mM, respectively (Figure 7C).
Discussion
The orphan HER2/Neu (ErbB2) receptor plays a critical role in
the cellular responses mediated by ligand-dependent activation
of ErbB coreceptors (Yarden and Sliwkowski, 2001). Indeed,
overexpression of Neu alone or in combination with EGFR or
HER3 can transform mammary epithelial cells and fibroblasts
(Pierce et al., 1991; Zhang et al., 1996). Transgenic mice31
A R T I C L EFigure 5. EGFR inhibitors are inactive against cells expressing HER2YVMA
A: MCF10A cells expressing HER2WT or HER2YVMA were treated for 24 hr with erlotinib, gefitinib, or lapatinib at the indicated concentrations. Cell lysates were
prepared, separated by SDS-PAGE, and subjected to immunoblots using the indicated antibodies.
B: Cells were treated with trastuzumab (10 mg/ml) followed by acid wash to remove bound antibody. Cell surface proteins were then biotinylated at 4ºC as
indicated in Experimental Procedures. Cell lysates were precipitated with Streptavidin Magnetic Spheres followed by HER2 immunoblot. To control for gel
loading, whole-cell lysates were subjected to HER2 and actin immunoblots (bottom panels).
C: Top: HER2WT- or HER2YVMA-expressing MCF10A cells were plated on basement membrane in 8-well chambers with or without erlotinib (3 mM), gefitinib (1 mM),
lapatinib (5 mM), trastuzumab (10 mg/ml), or the combination of lapatinib and trastuzumab as indicated in Experimental Procedures. Inhibitors were replen-
ished every 2 days. The phase contrast image shown was recorded 12 days after the initial seeding of cells. Scale bars, 50 mm. Bottom: 12-day acini were trypsi-
nized, and total cell number was determined in a Coulter counter. Each bar graph represents the mean 6 SD of four wells. p values were calculated using
Student’s t test.
D:At day 8 and day 14, HER2YVMA acini treated with the combination of lapatinib and trastuzumab were stained for b-catenin (green) and cleaved caspase-3
(red) (day 8), or Ki-67 (green) and Myc tag (red) (day 14). DAPI (blue), nuclear staining. Scale bars, 50 mm.32 CANCER CELL JULY 2006
A R T I C L EFigure 6. RNA interference of mutant HER2 inhibits survival of H1781 lung cancer cells
A: H1781 cells grown on 6-well plates were transfected by siRNA oligonucleotides targeting HER2WT, HER2MUT, or a control sequence. At day 3 after transfec-
tion, total RNA was extracted. Two hundred nanograms of RNA were used in the RT-PCR reaction as described in Experimental Procedures. Gene-specific
primer pairs were used to amplify HER2MUT, HER2WT, and b-actin cDNA (control). ‘‘/’’ lane indicates mock-transfected cells.
B: H1781 cells were lysed 3 days after transfection and analyzed by immunoblot using the indicated antibodies.
C: H1781 cells growing on glass coverslips were transfected by specific siRNA. At day 4 after transfection, cells were stained using antibodies against cleaved
caspase-3 (red) and Ki-67 (green). DAPI (blue), nuclear staining. Scale bar, 50 mm.
D: H1781 cells transfected with the indicated siRNA oligonucleotides were harvested by trypsinization 1 day posttransfection and seeded in soft agarose con-
taining the indicated inhibitors alone or in combination at the same concentrations used in Figure 5C. Colonies measuringR50 mm were counted at day 7.
Each bar represents the mean colony number 6 SD of 3 wells. p values were calculated using Student’s t test.overexpressing Neu in the mammary gland develop metastatic
mammary carcinomas (Guy et al., 1992). In these tumors, DNA
sequence analysis revealed the presence of juxtamembrane
deletions in the extracellular domain of Neu, resulting in a consti-
tutively active receptor capable of transforming fibroblasts (Sie-
gel et al., 1994). Such activating mutations have been reported
in primary human breast cancers (Siegel et al., 1999), although
their frequency remains unknown, and in two recent reports,
they were not confirmed (Stephens et al., 2004, 2005). The
most common change involving the proto-oncogene is mRNA
overexpression with or without gene amplification (Glockner
et al., 2001; Hirsch et al., 2002; Slamon et al., 1989). Recently,
however, two groups reported mutations in theHER2 gene con-
sisting of in-frame insertions within exon 20 in NSCLC (Shige-
matsu et al., 2005; Stephens et al., 2004). These alterations
are identical to mutations identified in the corresponding region
in the EGFR gene in lung cancers. More recently, Lee et al. re-
ported somatic mutations in exons 18–22 of the HER2 kinase
domain in gastric, colorectal, and breast carcinomas from Asian
patients (Lee et al., 2006).CANCER CELL JULY 2006In the present report, stable expression of HER2 containing an
in-frame YVMA insertion at residue 776 in nontumorigenic
BEAS2B (bronchial) and MCF10A (mammary) epithelial cells was
markedly more transforming than wild-type HER2. HER2YVMA
was more potent in inducing serum-free cell proliferation, motil-
ity, and tumorigenicity in vivo as well as preventing apoptosis
compared to HER2WT. In addition, it induced transphosphoryla-
tion of kinase-dead EGFR and exhibited higher ligand-indepen-
dent tyrosine phosphorylation and stronger association with
signal transducers that mediate proliferative and prosurvival
responses than HER2WT, indicating that the exon 20 insertion
endows the receptor with a gain of function.
Studies with cancer cell lines and human tumors have demon-
strated constitutive phosphorylation of (wild-type) HER2 (Ali-
mandi et al., 1995; Thor et al., 2000). The biochemical basis
for this constitutive activation is not clear but is consistent with
the reported ability of wild-type Neu to multimerize and become
activated when present in cells at high density (Samanta et al.,
1994). Thus, it is generally accepted that spontaneous dimeriza-
tion and activation of HER2 occurs in cancers with HER2 gene33
A R T I C L EFigure 7. CI-1033 inhibits mutant HER2-driven growth and signaling
A: MCF10A cells expressing HER2WT or HER2YVMA and H1781 cells were treated for 16 hr with CI-1033 at the indicated concentrations. Cell lysates were pre-
pared, separated by SDS-PAGE, and subjected to immunoblots using the indicated antibodies.
B: Top: HER2WT- or HER2YVMA-expressing MCF10A cells were plated on basement membrane in 8-well chambers with or without CI-1033. Inhibitors were replen-
ished every 2 days. Phase contrast image shown was recorded 12 days after the initial seeding of cells. Scale bars, 50 mm. Bottom: 12-day acini were trypsi-
nized, and total cell number was determined in a Coulter counter. Each bar graph represents the mean 6 SD of four wells.
C:H1781 cells were seeded in soft agarose containing the indicated concentration of CI-1033. Colonies measuringR50 mm were counted at day 7. Each bar
represents the mean colony number 6 SD of three wells.amplification. Another possible mechanism for activation of
the HER2 kinase is transactivation by ligand bound EGFR or
HER3/4. Indeed, coexpression of the EGFR ligand TGFa with Neu
in the mammary gland of transgenic mice markedly accelerates
tumor onset and progression compared to mice expressing
the Neu or TGFa transgenes alone. In this study, TGFa/Neu bi-
genicmice exhibited increased tyrosine phosphorylation of both
EGFR andNeu (Muller et al., 1996), providing evidence of EGFR-
Neu crosstalk and of the ability of HER2/Neu to amplify ligand-
activated EGFR signals.
On the other hand, EGFR function has been shown to be re-
quired for Neu-induced transformation. For example, EGFR
TKIs can markedly delay Neu-induced tumors in transgenic
mice (Lenferink et al., 2000; Lu et al., 2003). Further, MMTV/
Neu mice carrying a catalytically impaired EGFR (waved-2
mice) developed breast tumors only after a prolonged latency,
and the tumors that developed were fewer in number (Gillgrass
et al., 2003). In MCF10A/HER2WT cells, EGFR inhibition with
gefitinib blocks the gain-of-function effects of transfected
wild-type HER2 (Figure 5 and Ueda et al. [2004]). HER2-overex-
pressing cancers that also overexpress EGFR exhibit a worse
outcome compared to tumors with high HER2 but undetectable
EGFR (DiGiovanna et al., 2005). Finally, EGFR-positive NSCLCs
that also exhibit increased (wild-type) HER2 gene copy number
respond clinically to EGFR TKIs (Cappuzzo et al., 2005; Hirsch34et al., 2002), further suggesting that the EGFR is required for sig-
naling by wild-type HER2.
In BEAS2B and MCF10A cells, HER2YVMA potently induced
EGFR phosphorylation. This transactivation did not require the
EGFR tyrosine kinase in that it was also observed with catalyti-
cally dead K721R EGFR and was not blocked by the EGFR TKIs
erlotinib and gefitinib. These results suggest that in hetero-
dimers containing EGFR and exon 20 HER2 mutants, the
EGFR tyrosine kinase activity is dispensable. EGFR function
has been shown to be critical for the antiapoptotic signals gen-
erated by other oncogenes such as SOS (Sibilia et al., 2000).
Therefore, it is conceivable that transactivation of the EGFR is
also critical for the potent antiapoptotic effect of HER2YVMA. If
so, HER2 mutations would overlap functionally with EGFR acti-
vating mutations, perhaps explaining the reported lack of coex-
istence of these alterations in primary human tumors (Lee et al.,
2006; Shigematsu et al., 2005; Stephens et al., 2004).
The receptor-specific effects of EGFR and HER2 on transfor-
mation have been characterized in MCF10Amammary epithelial
cells expressing chimeric EGFR or HER2 that can be homodi-
merized by bivalent synthetic ligands (Muthuswamy et al.,
1999). In this system, activation of HER2, but not the EGFR,
has been shown to reinitiate proliferation and generate 3Dmulti-
acinar MCF10A structures with a filled lumen where apoptosis
is abrogated. In the study herein, HER2YVMA but not HER2WTCANCER CELL JULY 2006
A R T I C L EFigure 8. Schema of HER2YVMA signaling output
and potential response to ErbB inhibitors
Signaling by EGFR homodimers is brief and lim-
ited because of receptor endocytosis and deg-
radation following ligand-mediated activation
(Yarden and Sliwkowski, 2001) (left). Ligand-in-
duced heterodimers of EGFR and wild-type
HER2 are more stable and recruit additional
cytoplasmic transducers, thus signaling with in-
creased potency compared to EGFR homo-
dimers (Yarden and Sliwkowski, 2001). Probably
because of EGFR/HER2 transactivation, cells
driven by these heterodimers are sensitive to
EGFR TKIs (middle). In cells expressing the HER2
exon 20 insertion mutant, HER2 dimerizes consti-
tutively and associates with and transactivates
the EGFR. This HER2/EGFR transactivation
does not require the EGFR tyrosine kinase, ex-
plaining their resistance to EGFR TKIs. Although
at higher concentrations than those required to
inhibit EGFR and wild-type HER2 phosphoryla-
tion, lapatinib still inhibits HER2YVMA phosphoryla-
tion. Irreversible ErbB TKI CI-1033 inhibits both
HER2WT and HER2YVMA phosphorylation. Like
HER2WT, the mutant receptor is partially downre-
gulated from the cell surface by trastuzumab
(right), which also inhibits cells expressing this
mutation.behaved similarly to ligand-activated chimeric ErbB2 reported
byMuthuswamy et al. (2001) in the absence of AP1510, support-
ing the ability of the insertion mutant to potently engage antia-
poptotic signals in a ligand-independent fashion. Although
HER2WT was also phosphorylated, it associated with Shc and
p85 with lower efficiency and activated MAPK and Akt weakly
compared to HER2YVMA, thus potentially not reaching a thresh-
old required for the generation of sustained survival signals.
Inhibition of mutant HER2 with RNA interference in H1781
lung cancer cells, which contain a VC insertion at G776 in
exon 20 of the HER2 gene, inhibited P-MAPK and P-Akt, re-
duced proliferation, and induced cell death. These cells have
highly phosphorylated wild-type EGFR (Tracy et al., 2004) and
are insensitive to gefitinib and erlotinib (Figure 6). Of note, a sim-
ilar insertion is exon 20 of the EGFR is also resistant to these
EGFR TKIs (Greulich et al., 2005). However, direct inhibitors of
HER2 such as trastuzumab, lapatinib, and CI-1033 reduced
colony formation by MCF10A/HER2YVMA and H1781 cells. In
MCF10/HER2YVMA cells, treatment with trastuzumab downre-
gulated mutant HER2 from the cell surface, while lapatinib and
CI-1033 inhibited HER2 phosphorylation, further suggesting
that cancers expressing this mutant remain HER2 dependent
and thus sensitive to HER2-targeted therapies. Clinical data to
support this possibility are not available, since there are no
published trials with single-agent trastuzumab or lapatinib in
NSCLC, where a low frequency of HER2 mutations has been
reported. Thus, the therapeutic efficacy of anti-HER2 strategies
in this patient population requires prospective investigation.
Finally, and based on the results with MCF10A and H1781
cells treated with erlotinib and gefitinib, we propose, first, that
EGFR inhibitors would be effective against tumors driven by het-
erodimers of EGFR andwild-typeHER2. In these cancers, HER2
amplifies signals by EGFR/HER2 heterodimers, which remain
dependent on the EGFR kinase (Figure 8). This possibility is sup-
ported by a recent report in which EGFR-positive NSCLCs with
wild-typeHER2 gene amplification responded clinically to EGFRCANCER CELL JULY 2006TKI gefitinib (Cappuzzo et al., 2005). In a recent randomized
survival study of erlotinib versus best supportive care in NSCLC
patients (Shepherd et al., 2005), this correlation with clinical
response remains to be investigated. Second, we predict that
cancers expressing mutation/insertions in exon 20 of HER2
would be insensitive to small molecule inhibitors of the EGFR ty-
rosine kinase. Indeed, in a very recent study from Korea, all four
patients with lung adenocarcinoma containing HER2 mutations
progressed on gefitinib. Three of the four containedmutations in
exon 20 (Han et al., 2006). Third, in these cancers, a combination
of trastuzumab and lapatinib or the irreversible HER2 inhibitor
CI-1033 may have clinical activity and is worthy of prospective
investigation.
Experimental procedures
Cell lines, plasmids, and viruses
All cells were from the American Type Culture Collection (ATCC). Cell culture,
plasmid cloning, and retroviral transduction were carried out according to
standard procedures (details provided in Supplemental Data). The following
reagents were used: human TGFa and EGF (Calbiochem), puromycin (Cal-
biochem), G418 (Research Products International Corp.), erlotinib (from
Mark Sliwkowski, Genentech), gefitinib (from Alan Wakeling, AstraZeneca
Pharmaceuticals), lapatinib (from Tona Gilmer, GlaxoSmithKline), and CI-
1033 (from David Fry, Parke-Davis). Trastuzumab was purchased at the Van-
derbilt University Medical Center Pharmacy. The EGFRK721R-GFP plasmid
was kindly provided by Brent Polk (Vanderbilt University).
Immunoprecipitation and immunoblot analysis
Immunoprecipitation and immunoblot analysis were performed using stan-
dard protocols (details provided in Supplemental Data).
Cell growth, apoptosis, and motility assays
Equal numbers of cells were seeded on 12-well plates and allowed to grow in
full medium. Cells were harvested by trypsinization every 24 hr, and cell num-
ber was determined in a Coulter counter. Cells growing on 100 mm dishes
were serum starved for 3 days and collected for apoptosis assay using an
Apo-BrdU kit (Phoenix Flow Systems, Inc.) according to the manufacturer’s35
A R T I C L Eprotocol. FITC-positive apoptotic cells were quantitated in a FACS/Calibur
Flow Cytometer (BD Biosciences).
For wound closure assays, cells were allowed to reach confluence on a 6-
well plate and then serum starved for 24 hr. The monolayers were scraped
with a plastic pipette tip and replenished with fresh serum-free medium.
Phase contrast images were photographed at 0, 10, and 24 hr after wound-
ing. Transwell motility assays were performed utilizing 5 mm pore, 6.5 mm
polycarbonate transwell filters (Corning Costar Corp.). Cells (1.5 3 105 per
well) were seeded in serum-free medium onto the upper surface of the filters
and allowed tomigrate. After 24 hr, the cells on the upper surface of the filters
were wiped off with a cotton swab. Cells that hadmigrated to the filter under-
side were fixed, stained with Diff-Quik stain set (Dade Behring, Inc.), and
counted by bright field microscopy.
Soft agarose colony-forming assay
Base layers consisting of growth medium containing 0.8% low-melting point
agarose (Gibco) and 10 mM HEPES (pH 7.5) were poured onto 6-well plates
and allowed to solidify. Cells (33 104 per well) were plated in triplicate in top
layers consisting of growth medium containing 0.4% agarose and 5 mM
HEPES. Colonies measuring R50 mm were photographed after 7–10 days
and counted manually.
Xenograft studies
Exponentially growing cells on 150 mm dishes were scraped off and resus-
pended in serum-free medium; 23 106 cells in 0.3 ml were then injected sub-
cutaneously via a 22-gauge needle into each of 4-week-old female athymic
nudemice (Harlan Sprague-Dawley). Tumor formation wasmonitored by pal-
pation twice a week. Volume of tumors measuringR3 mm in diameter was
calculated by the formula: volume = width2 3 length/2. These experiments
were approved by the Vanderbilt Institutional Animal Care Committee and
performed under institutional guidelines in accordance with approved regu-
latory standards.
Three-dimensional morphogenesis and indirect
immunofluorescence
MCF10A cells expressing HER2WT, HER2YVMA, or vector were seeded on
Growth Factor Reduced Matrigel (BD Biosciences) in 8-well chamber slides
following the protocol described by Debnath et al. (2003) Morphogenesis of
acini was photographed every 2 days. For cell number counting, cultures
growing on Matrigel were trypsinized and cell numbers were measured in
a Coulter counter. Invasion assay was performed in BD BioCoat Growth
Factor Reduced Matrigel invasion chambers (BD Biosciences) according
to the manufacturer’s protocol. Immunofluorescence staining of 3D acini
was performed as described by Debnath et al. (2003) using antibodies
against b-catenin (BD Biosciences), cleaved caspase-3 (Cell Signaling),
Ki-67 (Calbiochem), and Myc tag. Confocal analyses were performed with
Zeiss inverted LSM510 confocal microscopy system. Indirect immunofluo-
rescence assay (IFA) was performed as described previously (Wang et al.,
2005). Fluorescent images were captured using a Princeton Instruments
cooled CCD digital camera from a Zeiss Axiophot upright microscope. Pri-
mary antibodies include Ki-67 and cleaved caspase-3. The fluorescent
antibodies are Oregon green-a-mouse IgG and Texas red-a-rabbit IgG
(Molecular Probes).
Transfection of DNA and siRNA, total RNA extraction, and RT-PCR
Cell transfection, RNA extraction, and RT-PCR were performed using stan-
dard protocols (details provided in Supplemental Data).
Cell surface biotinylation
Cells plated in 100mmdisheswere treated or not with trastuzumab (10 mg/ml)
for 24 hr at 37ºC and washed with PBS. Bound antibody was removed by in-
cubating cells for 6 min on ice with cold acid wash buffer (0.5 M NaCl, 0.2 M
sodium acetate [pH 3.0]). After three washes with cold PBS (pH 8.0), cells
were incubated with freshly prepared Sulfo-NHS-Biotin reagent (2 mM;
Pierce) for 30 min at 4ºC. The reaction was quenched with 100 mM glycine
in PBS, and the cells were lysed in NP-40 buffer. Equal amounts of protein
extracts (500 mg) were subjected to precipitation using Streptavidin Magnetic
Spheres (Promega) followed by SDS-PAGE and HER2 immunoblot.36In vitro kinase assays
Five hundred micrograms of total protein extracted from MCF10A/HER2WT
or MCF10A/HER2YVMA cells were immunoprecipitated with a Myc tag anti-
body. The precipitates were washed twice in NP-40 lysis buffer, twice in
kinase buffer (20 mM HEPES [pH 7.5], 10 mM MgCl2, 10 mM MnCl2, 1 mM
dithiothreitol, 0.1 mM Na3VO4), and then aliquoted on ice into two equal por-
tions, each brought up to a final volume of 40 ml by adding kinase buffer. ATP
was added to one aliquot (final concentration 0.1 mM) but not to the other
aliquot. The kinase reaction was allowed to proceed for 5 min at 30ºC and
then terminated by adding 53 loading buffer and boiling for 3 min before
separation by 7.5% SDS-PAGE followed by immunoblot analysis. In the re-
action using kinase-dead EGFR as substrate, the EGFRK721R-GFP plasmid
was transiently expressed by 32D cells followed by precipitation using
a GFP antibody. Precipitated EGFRK721R-GFP was incubated with HER2WT,
HER2YVMA receptors, or control precipitates in the absence or presence of
0.1 mM ATP. A kinase reaction was carried out under the same conditions
as above, and its products were resolved by 7.5%SDS-PAGE and visualized
by P-Tyr, EGFR, and Myc immunoblot analyses.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/1/25/DC1/.
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